MSD Animal Health to launch new Cobactan SRD therapy in Europe

MSD Animal Health has announced European launch plans for Cobactan LA 7.5 Percent, a new long-acting treatment for swine respiratory disease (SRD).

The new-generation injectable antimicrobial – which is an alternate version of the older Cobactan 2.5 Percent product – has been granted regulatory approval in 21 European nations.

It is administered via two intramuscular injections 48 hours apart, providing a short withdrawal period and efficacy against three major SD pathogens – Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida.

Raul Berro, global marketing director for swine at MSD Animal Health, said: "Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."

It represents an important new treatment option against SRD, a condition which causes 44.2 percent of nursery deaths and 61.1 percent of adult deaths in the global swine industry.

This comes after the company recently launched Panacur AquaSol, a new water-administered wormer for pigs.